Drug intelligence / Profile preview

FL-102

Development stage: Preclinical
Lead developer: 1ST Biotherapeutics
Modality: Small Molecules

Overview

FL-102 is an early-stage oncology drug candidate currently in the discovery phase, developed through a strategic partnership between First Biotherapeutics (1ST Biotherapeutics) and LigaChem Biosciences (formerly LegoChem Biosciences). The program is part of a joint pipeline established in late 2024 and expanded in 2025, which focuses on the development of novel antibody-drug conjugate (ADC) payloads and small-molecule immuno-oncology assets. As of early 2026, the specific biological target and mechanism of action for FL-102 remain undisclosed by the developers. The candidate is being advanced by leveraging First Biotherapeutics' expertise in small molecule discovery and LigaChem's platform technologies to address unmet needs in the oncology space.

Beyond the preview

Go deeper on FL-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FL-102.

Explore the full profile